|
FY2026
12 months to Jan 31, 2026
|
FY2025
12 months to Jan 31, 2025
|
FY2024
12 months to Jan 31, 2024
|
FY2023
12 months to Dec 31, 2022
|
FY2022
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Stock-based compensation | |||||
| Amortization of beneficial conversion feature | |||||
| Amortization of debt discount | |||||
| Change in assets and liabilities: | |||||
| Prepaid expenses | |||||
| Other receivable | |||||
| Accounts payable and accrued expenses | |||||
| Accrued expenses - related party | |||||
| Accounts payable and accrued expenses - related party | |||||
| Accrued interest | |||||
| Net cash used in operating activities | |||||
| Cash flows from financing activities: | |||||
| Proceeds from convertible notes payable | |||||
| Proceeds from note payable | |||||
| Proceeds from notes payable to related party | |||||
| Repayment of debenture | |||||
| Proceeds from exercise of warrants | |||||
| Proceeds from sale of preferred stock, net | |||||
| Net cash provided by financing activities | |||||
| Net (decrease) increase in cash | |||||
| Cash at beginning of period | |||||
| Cash at end of period | |||||
| Cash paid for interest | |||||
| Non-cash investing and financing activities: | |||||
| Conversion of liabilities into common stock | |||||
| Conversion of convertible notes payable | |||||
| Cashless exercise of warrants and options | |||||
| Conversion of accounts payable into common stock | |||||
Loading...